Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz Sells 20,000 Shares

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the transaction, the director now directly owns 3,402,584 shares in the company, valued at $115,381,623.44. This represents a 0.58 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Simulations Plus Stock Up 2.0 %

Shares of NASDAQ:SLP traded up $0.70 during midday trading on Friday, reaching $36.28. The company's stock had a trading volume of 158,778 shares, compared to its average volume of 215,492. The firm has a market capitalization of $728.87 million, a PE ratio of 90.70 and a beta of 0.83. The stock has a fifty day moving average of $30.81 and a 200 day moving average of $32.44. Simulations Plus, Inc. has a twelve month low of $24.00 and a twelve month high of $51.22.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on SLP shares. StockNews.com downgraded Simulations Plus from a "hold" rating to a "sell" rating in a research report on Monday, November 4th. William Blair reiterated an "outperform" rating on shares of Simulations Plus in a research report on Wednesday, January 8th. Stephens initiated coverage on Simulations Plus in a research report on Friday, November 15th. They set an "overweight" rating and a $39.00 target price for the company. KeyCorp upped their price objective on Simulations Plus from $35.00 to $37.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Finally, BTIG Research lowered their target price on shares of Simulations Plus from $60.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Simulations Plus currently has an average rating of "Moderate Buy" and an average target price of $49.40.

Hedge Funds Weigh In On Simulations Plus

Institutional investors have recently made changes to their positions in the company. Barclays PLC increased its position in shares of Simulations Plus by 390.6% in the third quarter. Barclays PLC now owns 28,473 shares of the technology company's stock valued at $911,000 after buying an additional 22,669 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Simulations Plus by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company's stock worth $14,367,000 after purchasing an additional 18,924 shares during the last quarter. State Street Corp lifted its stake in Simulations Plus by 4.7% in the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company's stock valued at $20,503,000 after buying an additional 28,953 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Simulations Plus by 106.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company's stock worth $1,517,000 after buying an additional 24,371 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Simulations Plus by 402.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company's stock worth $1,279,000 after buying an additional 32,002 shares in the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.